MedTrace Logo

Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial

NCT01798602 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2013-02-26

No results posted yet for this study

Summary

The CHAT Pilot Trial is designed to compare rosuvastatin against placebo in patients with suspected H1N1. The pilot study will assess the feasibility of our clinical protocols, and study procedures.

Conditions

  • H1N1 Influenza

Interventions

DRUG

Rosuvastatin or identical placebo

Tablet crushed for administration via feeding tube

DRUG

Placebo

Identical placebo for rosuvastatin

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • The Physicians' Services Incorporated Foundation

    collaborator OTHER

  • Public Health Agency of Canada (PHAC)

    collaborator OTHER_GOV

  • Canadian Critical Care Trials Group

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-05-31
Completion
2010-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01798602 on ClinicalTrials.gov